Clinical Trials
Several clinical trials evaluate potassium chloride across conditions such as vascular function, coronary artery disease, fluid balance, drug interactions, and carpometacarpal joint arthritis. Sponsored by academic institutions and government organizations, these Early Phase 1, Phase 1, and unassigned protocols examine physiological outcomes including the vascular effects of potassium salt substitution in healthy individuals and patients with diabetes. Current trial recruitment statuses include recruiting, active not recruiting, and not yet recruiting.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06359665 | Not yet recruiting | Arthritis of Carpometacarpal Joint of Left Thumb|Arthritis of Carpometacarpal Joint of Right Thumb |
Brent DeGeorge|University of Virginia |
2024-06-01 | Phase 1 |
| NCT06194864 | Recruiting | Drug Interaction |
Emalex Biosciences Inc.|Syneos Health|Cambridge Cognition Ltd |
2024-01-18 | Phase 1 |
| NCT05970601 | Not yet recruiting | Vascular Function|Healthy|Diabetes |
Prof. Dr. med. Johannes Stegbauer|Heinrich-Heine University Duesseldorf |
2023-08-01 | Not Applicable |
| NCT05775055 | Active not recruiting | Fluid Balance Outcomes |
Loughborough University|entrinsic bioscience LLC |
2023-03-14 | Not Applicable |
| NCT05625490 | Recruiting | Coronary Artery Disease |
Washington University School of Medicine|National Institutes of Health (NIH)|National Heart Lung and Blood Institute (NHLBI) |
2022-11-11 | Early Phase 1 |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).